Language:

Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC

The New England journal of medicine, 2020-10, Vol.383 (14), p.1328-1339 [Peer Reviewed Journal]

Copyright © 2020 Massachusetts Medical Society. All rights reserved. ;Copyright © 2020 Massachusetts Medical Society. ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa1917346 ;PMID: 32997907

Full text available

Citations Cited by

Actions
1. Add to My Research
2. Remove from My Research
3. E-mail
4. Print
5. Permalink
6. Citation
7. EasyBib
8. EndNote
9. RefWorks
10. Delicious
11. Export RIS
12. Export BibTeX

Title:
Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC
Author: Herbst, Roy S ; Giaccone, Giuseppe ; de Marinis, Filippo ; Reinmuth, Niels ; Vergnenegre, Alain ; Barrios, Carlos H ; Morise, Masahiro ; Felip, Enriqueta ; Andric, Zoran ; Geater, Sarayut ; Özgüroğlu, Mustafa ; Zou, Wei ; Sandler, Alan ; Enquist, Ida ; Komatsubara, Kimberly ; Deng, Yu ; Kuriki, Hiroshi ; Wen, Xiaohui ; McCleland, Mark ; Mocci, Simonetta ; Jassem, Jacek ; Spigel, David R
Subjects: Adult ; Aged ; Aged, 80 and over ; Antibodies, Monoclonal, Humanized - adverse effects ; Antibodies, Monoclonal, Humanized - therapeutic use ; Antineoplastic Agents - adverse effects ; Antineoplastic Agents - therapeutic use ; Antineoplastic Combined Chemotherapy Protocols - adverse effects ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Apoptosis ; B7-H1 Antigen - metabolism ; Carboplatin - administration & dosage ; Carcinoma, Non-Small-Cell Lung - drug therapy ; Carcinoma, Non-Small-Cell Lung - genetics ; Carcinoma, Non-Small-Cell Lung - metabolism ; Carcinoma, Non-Small-Cell Lung - mortality ; Carcinoma, Squamous Cell - drug therapy ; Chemotherapy ; Cisplatin - administration & dosage ; Deoxycytidine - administration & dosage ; Deoxycytidine - analogs & derivatives ; Epidermal growth factor receptors ; Female ; Humans ; Immunotherapy ; Lung cancer, Non-small cell ; Lung Neoplasms - drug therapy ; Lung Neoplasms - genetics ; Lung Neoplasms - metabolism ; Lung Neoplasms - mortality ; Male ; Metastases ; Metastasis ; Middle Aged ; Monoclonal antibodies ; Mutation ; Non-small cell lung carcinoma ; Patient outcomes ; PD-L1 protein ; Platinum ; Population ; Small cell lung carcinoma ; Survival Analysis ; Targeted cancer therapy ; Translocation ; Tumor cells ; Tumor-infiltrating lymphocytes ; Tumors
Is Part Of: The New England journal of medicine, 2020-10, Vol.383 (14), p.1328-1339
Description: Among patients with lung cancer that expressed programmed death ligand 1, the anti–PD-L1 antibody atezolizumab was compared with chemotherapy in a randomized trial. In the subgroup with the highest PD-L1 expression, the median overall survival was 20.2 months with atezolizumab and 13.1 months with chemotherapy.
Publisher: United States: Massachusetts Medical Society
Language: English
Identifier: ISSN: 0028-4793
EISSN: 1533-4406
DOI: 10.1056/NEJMoa1917346
PMID: 32997907
Source: ProQuest One Psychology
AUTh Library subscriptions: ProQuest Central
MEDLINE

Back to results list


INSPIRE LIBRARY - TON DUC THANG UNIVERSITY	(84-028) 37 755 057	Feedback
19 Nguyen Huu Tho St. Dist.7, HCM	thuvien@tdtu.edu.vn	Feedback

Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC

Copyright © 2020 Massachusetts Medical Society. All rights reserved. ;Copyright © 2020 Massachusetts Medical Society. ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa1917346 ;PMID: 32997907

Searching Remote Databases, Please Wait